The invention relates to a Substance which lowers LDL cholesterol levels in serum and which is fat soluble B-sitostanol fatty acid ester, and to a method for preparing and using the Same. The Substance can be taken orally as a food additive, food Substitute or Supplement. A daily con Sumption of the B-sitoStanol ester in an amount between about 0.2 and about 20 g/day has been shown to reduce the absorption of biliary and endogenic cholesterol. U.S. Patent The degree of cholesterol absorption depends on a heredi tary property, apoprotein E-phenotype. Apoprotein E is a protein which belongs to Serum lipoproteins and takes part in the transport of cholesterol in the system (26) . Of alleles asSociated with the Synthesis of apoprotein E, i.e. the lipo protein which affects absorption, there are known three types, e2, e3, and e4, which combine in pairs at random. Alleles are capable of forming in total Six different combi nations. The higher the sum of the Subindices, the better absorbable the cholesterol and the higher the level of cholesterol, in particular bad LDL cholesterol, in the Serum (27) . e4 allele is over represented among the hereditary factors of Finns, So that its proportion is almost double as compared with many European populations (28) . Serum cholesterol levels can be lowered by dietary means, by paying attention to the quantity and type of the fat ingested and to the amount of cholesterol intake. In practice, however, these means do not always lead to a Satisfactory end result. Other methods, Suitable for the entire population, for reaching Serum cholesterol levels lower than the present ones must be Searched for. Increasing the fiber content of food is a method of limited effect. The cholesterol-lowering effect of soluble fiber in food is based on the binding and removal of bile acids. Since the absorption of cholesterol is of fundamental significance in the regulation of the choles terol level in Serum, it is logical to aim at developing methods by which the absorption of cholesterol can be prevented or reduced. scantily absorbed into the system (less than 10% of the sterols) (30, 31, 32) are excreted in the bile and through that in the Stools. At present it is easy to measure Sterol levels from food, Serum or Stool Samples by gas chromatographic methods. The levels in Serum are in part dependent on the plant Sterol amounts derived from the diet and in part on the efficiency of the absorption of Sterols. In general the plant sterol levels in serum remain below 1/300 of the serum cholesterol level, Since the absorbed plant Sterol fraction is excreted from the system in the bile.
Even large ingested doses of plant Sterols do not show in Serum plant Sterol levels. The values remain at the normal level, Since in man the plant Sterol absorption capacity is rapidly Saturated. The Serum plant Sterol level rises to a detrimental level in a few rare diseaseS Such as cerebroten dinotic Xanthomatosis and sitosterolemia (33, 34, 35) , in connection with which coronary disease is common. The incidence of these diseases is at maximum a few cases in a population of one million. Not a single case of these diseases has been observed in Finland. High plant sterol values are at times observed in patients Suffering from certain hepatic diseases (36) .
Studies of the metabolism of cholesterol have shown that sitosterol inhibits the absorption of both endogenic and dietary cholesterol from the intestines (13, 14) . As a result of this, the excretion of neutral Steroids in the Stools increases, which leads to a shortage of cholesterol in the liver and through that to a decreased Serum cholesterol level. On the other hand, sitosterol does not affect the absorption of bile acids (13) .
On the basis of experiments on animals, it seems that the action of Sitosterol is based on its ability to displace dietary cholesterol in bile acid micelli (15, 16, 17) . Similar results have also been obtained in man (37) . Various plant sterols have been demonstrated to affect in different ways the absorption of cholesterol (19, 38) . Previous studies carried out on experimental animals give the impression that Sito stanol is the most effective inhibitor of cholesterol absorp tion (38) dissolved in fat decreased the absorption of cholesterol in the test subjects on average by 33% (25). In the same study, sitosterol mixed with food and in a lower dose (1 g/day) decreased the absorption of cholesterol by 42%.
A German patent (Deutsches Patentamt, OffenlegungSS chrift 25 2035069/Jan. 28, 1971) relates to the adding of plant Sterol fatty acid esters to cooking oil with the objective of lowering the Serum cholesterol levels in man. The Said patent proposes for use in the esterification of free Sterols a. method which in no case fulfills the requirements for the preparation of a food-grade product. According to the patent, the esterification is carried out between a free Sterol and a fatty acid anhydride, with perchloric acid acting as a cata lyst. The catalyst and reagent used cannot be accepted in a food process. In addition, the Said patent relates to the fatty acid esters of only native plant Sterols.
Many reagents which cannot be accepted as a food or for the production of a product intended as an additive for foods have been used in the preparation of Sterol fatty acid esters.
The use of, for example, chlorine (39) 
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the use of a Sterol of an entirely different type for lowering the cholesterol level in serum. What is involved is fatty acid esters of 5C.-saturated Sterols, especially Sitostanol fatty acid esters (sitostanol=24 ethyl-5C.-cholestane-3?-ol) which have been observed to lower cholesterol levels in Serum with particular efficacy. The Said esters can be prepared or used as Such, or they can be added to foods, especially to the fatty part of a food. The Sitostanol fatty acid ester mixture is prepared by hardening or hydrogenating a commercial B-sitosterol mixture (sitosterol=24-ethyl-5C.-cholestane-3B-ol). B-sitostanol can be prepared by a prior known cholesterol hardening tech nique by hardening B-Sitosterol by means of a Pd/C catalyst in an organic solvent (43) . A hardening degree of over 99% is achieved in the reaction. The catalyst used in the hard ening is removed by means of a membrane filter and the obtained Sitostanol is crystallized, washed and dried. In accordance with the invention, the B-sitostanol mixture, which contains campestanol approx. 6%, is esterified with different fatty acid ester mixtures by a commonly known chemical interesterification technique (44, 45, 46) . A methyl ester mixture of the fatty acids of any vegetable oil can be used in the reaction. One example is a mixture of rapeseed oil and methyl ester, but any fatty acids which contain approx. 2-22 carbon atoms are usable.
The method according to the invention for the preparation of Stanol fatty acid esters deviates advantageously from the previously patented methods in that no Substances other than free Stanol, a fatty acid ester or a fatty acid ester mixture, and a catalyst are used in the esterification reaction. The catalyst used may be any known interesterification catalyst Such as Sodium ethylate.
It is also to be noted that in the method used in our application, contrary to the method of Balties, referred to above, the fat itself is not interesterified. In this case the fatty part of a fat preparation or Some other food will retain its natural properties. It should be noted further that the inter S esterified mixture can be added directly to fat-containing foods or be used as Such. Since the Stanol part of the mixture is non-absorbable, the energy content of the Stanol fatty acid ester mixture is only 20-40% of the energy content of a conventional oil or fat, depending on the fatty acid compo Sition. Thus the mixtures can be used advantageously also as Substances decreasing the energy content or caloric value of a food.
The action of B-sitoStanol fatty acid ester on cholesterol absorption and on Serum cholesterol levels has not been Studied previously. One Study on which this application is based, investigated how plant Sterol concentrations in Serum were affected by sitostanol (composition: B-sitostanol 94% and campestanol 6%),a hardened form of Sitosterol, dis solved in rapeseed oil, both free and in the form of a fatty acid ester. The test arrangement of the Study is as follows:
Intervention Study TEST 
GROUPS (N-22) ---------------------------------------------------control (n-8)
:
B-sitostanol (n = 7)
*-----------------B-sitostanol ester (n -7) ---------------------------------------------------:
Owk. The results also show that an intake of B-sitostanol in a soluble form-i.e. in the form of fatty acid esters reduced the absorption of plant sterols more effectively than did free Respectively, the changes caused by Stanol additions in the total and LDL Serum cholesterol concentrations and in cholesterol absorption were also measured and these changes are shown in Table 2 . The control group consumed ordinary rapeseed oil without Stanol additions. Cholesterol absorption was effectively reduced by a f3-sitostanol fatty acid ester mixture (27.4%) even if the stanol intake was relatively low, 895 mg/day. The choles terol absorption of the control group did not change. The action of free B-sitostanol and a B-sitostanol fatty acid ester mixture on the cholesterol concentration in Serum, as com pared with the control group, is seen in Table 3:   TABLE 3 Effect in serum of B-sitostanol added to rapeseed oil on cholesterol levels. A B-sitoStanol fatty acid ester mixture decreased both total cholesterols and LDL cholesterol more effectively than did rapeseed oil and free B-sitoStanol. A B-sitostanol fatty acid ester mixture dissolved in rapeseed oil (3.2 g off-sitostanol/ day) decreased total cholesterol by 9.5% more and LDL cholesterol by 11.6% more than did rapeseed oil alone. Respectively, the HDL/LDL cholesterol ratio rose significantly, from 0.32 to 0.52. The studies carried out show clearly that by the addition of B-sitostanol fatty acid esters to, for example, food fats, Significant advantages can be achieved both in the national nutrition and in the treatment of hypercholesterolemia, Since 1) the mixture lowers cholesterol values in Serum, 2) the mixture does not increase Serum plant Sterol concentrations, 3) the mixture can be used daily as a fat Substitute in cooking normal food, even in large doses (0.2-20 g/d), whereby the intake of energy (calories) from fat decreases. 7 Lipid changes caused by B-sitostanol fatty acid esters, observed in the Study, are to be considered highly significant from the viewpoint of health. The significance of the results is emphasized by the possibility of using the compound alongside food preparations as part of ordinary cooking and an ordinary diet. Research results show that during an intervention diet the B-sitoStanol level in Serum does not rise, and that the levels of other plant Sterols in the Serum decrease. Thus the Said B-Sitostanol ester mixture is Safe also for those few individuals who readily absorb all sterols or who have disturbances in Sterol excretion. Furthermore, daily fat Substitution decreases an individuals energy Supply, Since the effective B-sitostanol compound is not absorbed, i.e., it acts as a non-energy producing part of fat. There is no evidence of the Said B-sitostanol ester mixture hampering the absorption of lipid-soluble vitamins or the vitamin levels in Serum.
Stanol Added to
The uses of a B-sitostanol fatty acid ester mixture as a part of various fats and oils in fat-containing products are wide, Since the physical properties of the mixture can be modified easily by altering the fatty acid composition of the mixture. In addition to this, the fatty acid composition of the B-sitostanol fatty acid ester mixture can be Selected So as to contain large amounts of monoenes and polyenes, whereby its efficacy in lowering the cholesterol levels in Serum are enhanced.
Since the B-sitostanol fatty acid ester mixture is prepared using raw materials belonging to normal food and produc tion processes generally used in the food industry, there are no obstacles to the production and use of the compound. For example, but without limitation, the Sitostanol ester is useful in Such foods as cooking oils, margarines, butter, mayonnaise, Salad dressings, and shortenings.
To test the long-term tolerability and hypocholesterolemic effect of 3-sitostanol esters, a one year long randomized double blind study was performed. The ester was adminis tered as a B-sitoStanol ester rich margarine and the effect of this margarine was Studied in a randomly Selected mildly hypercholesterolemic population Sample of 150 perSons.
The participants were recruited from the random popula tion of about 1500 previously studied for serum total and HDL cholesterol and triglycerides. The major selection criteria were as follows: Serum total cholesterole5.58 mmol/l, triglycerides <3 mmol/liter, age 25-65 years, BMI-30, stable medication for hypertension, diabetes or coronary heart disease and absent renal, alcohol, liver or thyroid problems. Males accounted for 42% of the popula tion.
After a fasting blood Sample the participants replaced 24 g/day of their dietary fat for 6 weeks through a rapeseed oil based margarine. The major fatty acid of this margarine was: C16:0=16.7%, C18:1=47.3%, and C18:3=8.9%. The total amount of trans fatty acids was 0.5%. The margarine was distributed as 8 gram portion packs to be used on a slice of bread with breakfast, lunch, and dinner. The actual amounts of margarine consumed per portion pack ranged, as mea sured during different times of the study, from 7.3 to 7.7 grams.
At the end of the 6-week period, the perSons were randomized to either continue on their rapeseed oil based margarine without added f-sitostanol ester (control group: n=50) for 12 months or to change to the same margarine with f-sitostanol ester added (sitostanol ester group: n=100). The daily intake of B-sitostanol was intended to be 3 grams. After a 6-month period the Sitostanol ester group was rerandom ized to continue either on a daily intake of B-sitoStanol of either 3 gram (n=50) or 2 gram (n=50). The persons were not No side effects were reported. Data obtained showed that C-tocopherol content in Serum in the 50 participants on margarine without B-sitostanol ester was 17.11.8 mg/dl after the initial 6-week period with control margarine and 18.7+1.5 mg/dl at 12 months. The respective values in the f3-sitostanol ester groups were 15.1+1.0 (before the use of f-sitostanol ester containing margarine) and 13.8-t1.4 mg/dl (with f3-sitostanol ester). Thus, the changes in the two groups were not significantly different from each other. The lower ing of LDL cholesterol (major transporter lipoprotein for C-tocopherol) by 15% could clearly explain the nonsignifi cant decrease in C-tocopherol in the B-sitostanol ester groups. It can be postulated that the C-tocopherol concen tration of the remaining LDL particles is even higher after the use of B-sitoStanol ester.
Serum Lipids
The serum lipid values obtained is given in Table 4 . The baseline lipid levels were similar in the 3 groups. The use of the control margarine for the additional 12 months after the 6-week initial period did not change the Serum total, LDL, HDL cholesterol or triglycerides concentrations, but was followed by a significant increase in the Serum contents at the home diet. The data obtained shows that a simply modified dietary fat i.e., a regular margarine fortified with fat Soluble B-sitostanol esters decreases Serum total and LDL choles terol concentrations by about 11-15% in the mildly hyper cholesterolemic part of a randomly Selected population Sample. The findings of this study Suggests favorable effects of long-term use of B-sitostanol ester margarine to Substitute a part of the normal dietary fat intake. B-sitostanol itself is unabsorbable, does not appear to interfere detectably with the fat Soluble vitamins and is tasteless to the extent that it can be consumed in Sufficiently large amounts to cause a moderate cholesterol lowering effect in a relatively Small part of dietary fat. Thus, the partial substitution of dietary fat by B-sitostanol ester margarine is Suitable not only for the population-wide Strategy of lowering Serum cholesterol, but also as part of a Strategy to reduce hypercholesterolemia in the high-risk population. Thus, this kind of fat preparation is recommended for the general prevention of coronary heart disease and other atheromatous diseases in the population. Based on this study the preferred daily dose for B-sitostanol ester is 2.5-6.5 grams. EXAMPLE 1. Af-sitostanol ester mixture was prepared on a pilot Scale. 6 kg of B-sitostanol which had been dried overnight at 60 C. was esterified with 8.6 kg of a rapeseed oil methyl ester mixture. The esterification was carried out as follows: 
10
A mixture of B-sitostanol and rapeseed oil fatty acid methyl ester was heated in a reaction vessel at 900-120° C. and under a vacuum of 5-15 mmHg. The drying was continued for an hour, 12 g of Na ethylate was added, and the reaction was continued for approximately 2 hours. The catalyst was destroyed by adding water to the mixture. After phase Separation, the oil phase was dried under a vacuum.
A conversion of 98% was achieved in the reaction. The obtained ester mixture can be used as Such as an additive in fats.
Instead of a mixture of rapeseed oil fatty acid esters it is possible to use in the reaction a methyl ester or a methyl ester mixture of the fatty acids of any vegetable oil, espe cially of fatty acids which contain approximately 2-22 carbon atoms.
EXAMPLE 2
Before the Steam blowing of rapeseed oil, B-sitostanol ester mixture prepared in Example 1 was added, at 3, 6, and 13% by weight, to the rapeseed oil. Mayonnaise containing the said fat mixtures at 65% were prepared. The mayonnaise was prepared by homogenization by a known manner using a Koruma homogenizer.
There were no problems in the preparation of the mayonnaise, and their properties tested by Sense perception did not differ from those of conventional mayonnaise. EXAMPLE 3 Before the Steam blowing of oil, B-sitostanol ester mixture prepared in Example 1 was added, at 3 and 6% by weight, to the rapeseed oil.
The rapeseed oil to which the ester mixtures had been added remained clear at room temperature, and no perma nent turbidity was observed in it when it was stored at refrigerator temperatures. EXAMPLE 4 Other oils, Such as Sunflower, Soybean, olive and corn oil, can also be used as the oil in the products according to Examples 2 and 3. A margarine which contained fat 80% was prepared by a generally known method. The physical and Sense perceiv able properties of the margarine corresponded to those of conventional margarines. EXAMPLE 6 A five weeks double blind study was performed to show Serum cholesterol lowering effects of the margarine contain ing 12.5% B-sitostanol esters and to find out possible effects on the taste and palatability of the product.
A group of 24 perSons was randomized based on their blood Serum lipid values into two groups, a Stanol ester group and a control group. The Stanol ester group (n=12) consumed 3 portion packs of 8 g B-sitostanol ester enrich ment. All perSons knew that half of them got B-sitostanol ester enriched margarine and they were instructed to use the margarine on bread. The effect of the B-sitostanol esters on blood Serum lipid values were typical, with a reduction in total cholesterol and LDL cholesterol of 9% and 13%, respectively. At the end of the diet period each person was asked whether his/her margarine was enriched with B-sitostanol esters. The following answers concerning the margarine was obtained: I can't say 6 6 AS can be seen only 1 of 12 in the control group and 2 of 12 in the B-sitoStanol ester group gave the correct answer. This data clearly shows that incorporation of B-sitostanol ester in margarine even at as high levels as 12.5% do not cause any appreciable changes to the taste or other proper ties of the product.
